Janssen/Shire Reminyl
Executive Summary
Alzheimer's treatment slated for early 2001 launch after receipt of "approvable" letter July 31 from FDA, Shire said. While the agency has requested additional data, Janssen said it expects to be able to use currently available data to satisfy the request. Janssen filed the NDA for galantamine on Sept. 29, 1999
You may also be interested in...
Janssen/Shire Reminyl
"Hopefully we will be receiving the final [Reminyl] approval in a reasonable time frame," J&J CEO Ralph Larsen tells Jan. 23 analysts meeting. "We are prepared and have taken steps to introduce this important product into the U.S. very rapidly." The Alzheimer's agent galantamine has been "approvable" at FDA since July 31 (1"The Pink Sheet" Aug. 7, 2000, In Brief)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011